Cited by 30Virus-based gene therapy researchRetinal Development and DisordersRNA Interference and Gene Delivery

Simian Immunodeficiency Virus-Based Lentivirus Vector for Retinal Gene Transfer: A Preclinical Safety Study in Adult Rats

Ikeda, Y, Goto, Y, Yonemitsu, Y, Miyazaki, M, Sakamoto, T, Ishibashi, T, Tabata, T, Ueda, Y +3 more·2003·Gene Therapy

Abstract

Although lentivirus vectors hold promise for ocular gene therapy, they also have potential safety issues, particularly in the case of the current human immunodeficiency virus-based vectors. We recently developed a novel lentivirus vector derived from the nonpathogenic simian immunodeficiency virus from African green monkeys (SIVagm) to minimize these potentials. In this preclinical study, we evaluated whether SIV vector could be efficiently and safely applicable to retinal gene transfer by assessing the transgene expression, retinal function and histology over a 1-year period following subretinal injection in adult rats. The functional assessment via electroretinogram after both titers of SIV-lacZ (2.5 x 10(7) or 2.5 x 10(8) transducing units/ml) injection revealed both the dark and light adaptations to soon be impaired, in a dose-dependent manner, after a buffer injection as well, and all of them recovered to the control range by day 30. In both titers tested, the retinas demonstrated a frequent transgene expression mainly in the retinal pigment epithelium; however, the other retinal cells rarely expressed the transgene. Retinas exposed to a low titer virus showed no significant inflammatory reaction throughout the observation period, and also maintained the transgene expression over a 1-year period. In the retinas exposed to a high titer virus, however, mononuclear cell infiltration persisted in the subretinal area, and the retina that corresponded to the injected area finally underwent degeneration by around day 90. No retinal neoplastic lesions could be found in any animals over the 1-year period. We thus propose that SIV-mediated stable gene transfer might be useful for ocular gene transfer; however, more attention should be paid to avoiding complications when administering high titer lentivirus to the retina.

Integrity signals

Registry

Crossref · 10.1038/sj.gt.3301973

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In adult Male Wistar rats, low-dose SIV vector injected subretinally produced no inflammatory reaction by histology and stable long-term transgene expression persisting over 1 year, while high-dose SIV vector produced mononuclear cell infiltration in the subretinal area.

    “In a study aimed at evaluating the efficiency and safety of SIV vectors, a SIV vector was injected subretinally in adult Male Wistar rats at a low (2.5 × 10 7 TU/mL, TU: transducing unit) or high (2.5 × 10 8 TU/mL) dose.In the low dose group, no inflammatory reaction was observed by histology examinations, and this was accompanied by a stable long-term transgene expression which persisted over 1”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Ikeda, Y., Goto, Y., Yonemitsu, Y., Miyazaki, M., Sakamoto, T., Ishibashi, T., Tabata, T., Ueda, Y., Hasegawa, M., Tobimatsu, S., & Sueishi, K.
Affiliations
  • Kyushu University (JP)
  • Kagoshima University (JP)
  • ID Pharma (Japan) (JP)
Venue
Gene Therapy
Published
2003-06-30
Volume
10
Issue
14
Pages
1161-1169
ISSN
  • 0969-7128 (ISSN-L)
  • 1476-5462
OpenAlex
W2016450624
Cited by
30
References
32
Citations by year
2026: 1 · 2025: 1 · 2024: 2 · 2022: 1 · 2021: 1 · 2016: 2 · 2014: 1 · 2013: 1
FWCI
1.59
Type
journal article
Language
en
Open access
closed
Locations
  • Gene Therapy (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinal Development and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
simian immunodeficiency virus, lentiviral vectors, retinal gene transfer, ocular gene therapy, vector safety, subretinal injection, electroretinogram, retinal function, retinal pigment epithelium, mononuclear cell infiltration, retinal degeneration, transgene expression, chronic toxicity, vervet monkey
MeSH terms
Animals, Electroretinography, Genetic Vectors, Injections, Luminescent Proteins, Male, Necrosis, Retina, Retinal Diseases, Time Factors, Simian Immunodeficiency Virus, Genetic Therapy, Gene Expression, Rats, Wistar, Transgenes, Models, Animal, Green Fluorescent Proteins, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review